HC Wainwright Issues Negative Forecast for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright cut their Q1 2027 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a research note issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.40) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2027 earnings at ($0.02) EPS, Q4 2027 earnings at $0.68 EPS and FY2027 earnings at $0.59 EPS.

RYTM has been the subject of several other research reports. The Goldman Sachs Group lifted their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Rhythm Pharmaceuticals in a report on Tuesday, March 3rd. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Guggenheim boosted their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.13.

Rhythm Pharmaceuticals Stock Down 3.2%

NASDAQ RYTM opened at $87.45 on Friday. The company has a market cap of $5.97 billion, a PE ratio of -28.12 and a beta of 2.06. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20. The firm’s 50-day simple moving average is $99.04 and its two-hundred day simple moving average is $102.49.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. During the same quarter last year, the firm posted ($0.72) EPS. The firm’s revenue for the quarter was up 36.9% on a year-over-year basis.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the transaction, the chief accounting officer directly owned 160 shares in the company, valued at approximately $14,329.60. The trade was a 97.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 27,267 shares of company stock worth $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 39.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after buying an additional 1,407,313 shares in the last quarter. RA Capital Management L.P. boosted its stake in Rhythm Pharmaceuticals by 17.3% in the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after buying an additional 985,478 shares in the last quarter. Alliancebernstein L.P. grew its position in Rhythm Pharmaceuticals by 1,493.8% during the third quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after acquiring an additional 918,212 shares during the last quarter. JPMorgan Chase & Co. grew its position in Rhythm Pharmaceuticals by 445.5% during the second quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock valued at $49,513,000 after acquiring an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors purchased a new position in shares of Rhythm Pharmaceuticals during the third quarter worth approximately $60,417,000.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approved IMCIVREE (setmelanotide) for acquired hypothalamic obesity — the first and only therapy for this rare condition, expanding the label and potential patient population, which materially strengthens Rhythm’s commercial runway. Read More.
• Positive Sentiment: Rhythm named PANTHERx® Rare as the exclusive U.S. specialty pharmacy partner for the expanded IMCIVREE indication — this should improve patient access, distribution scale and support launch execution. Read More.
• Neutral Sentiment: Some brokers still assign above-current price targets (one report references a $133.19 consensus PT from select brokers), indicating divergent views on upside even after recent weakness. Read More.
• Neutral Sentiment: Investor/earnings-call coverage and transcripts are circulating (discussing the FDA approval and commercialization plans), useful for modeling uptake but not a direct catalyst on their own. Read More.
• Negative Sentiment: HC Wainwright reduced EPS forecasts across multiple quarters and cut its FY2027 outlook and price target (now $100) — the cuts lower near-term earnings expectations and likely contributed to selling pressure despite the firm maintaining a Buy rating. Read More.
• Negative Sentiment: Multiple brokers published pessimistic forecasts or lowered expectations (Bank of America, RBC, Needham, Citizens JMP), creating additional downward pressure and a wider dispersion of analyst views. Read More. Read More. Read More. Read More.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.